Trial Information - Phase I

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Disease Specifics: (HER2-)

Protocol ID: RGT-419B_01-101-1.0

Sponsor: Regor Pharmaceuticals, Inc.

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724